Strategic partnerships Aligos has active collaborations and licensing deals in HBV with Amoytop Biotech and Xiamen Amoytop Biotech for China; leverage these to position complementary co-development or regional commercialization opportunities in liver disease therapies.

Clinical stage potential As a clinical stage biotech focused on liver and viral diseases with a pipeline including HBV targets, there is opportunity to engage for late-stage partnerships, out-licensing, or strategic investments tied to upcoming trial milestones and potential US/EU regulatory filings.

Revenue growth Recent quarterly revenue in the multi‑million range and ongoing licensing revenue suggest a pattern of partner-funded development; approach potential customers or licensees with collaboration models that minimize upfront risk and align with milestone-based payments.

Industry press & events Active visibility through conferences and awards (BARDA SMART Prize collaboration) indicates opportunities to sponsor or co-present at upcoming healthcare conferences, increasing access to decision-makers in biotech and pharma.

Talent and leadership Key hires in business development and a strategic advisory network imply readiness for scalable partnering; target BD and alliance teams at mid-to-large biotechs seeking HBV or liver disease assets, especially those pursuing regional expansion or combination therapies.